Prognostic Significance of Pancreatic Metastases from Renal Cell Carcinoma in Patients Treated with Tyrosine Kinase Inhibitors.
The study aimed to define the true impact of pancreatic metastases (PM) from renal cell carcinoma on overall survival (OS) in patients treated with first-line tyrosine kinase inhibitors. Overall, 321 consecutive patients were analysed. The influence of PM on OS was assessed using the Kaplan-Meier estimator and the log-rank test (unadjusted and adjusted) and two multivariabe Cox proportional hazards regressions (CPHR). Thirty-four patients (10%) had PM and 287 (90%) had sites of metastasis other than the pancreas; the median OS was 46.1 and 23.1 months, respectively (unadjusted log-rank p=0.020; adjusted log-rank p=0.544). The PM status was an insignificant factor for OS in both CPHR (hazard ratio(HR)=0.84, p=0.603, and HR=0.66, p=0.098). The presence of PM was not an independent prognostic factor, but was rather an indicator of an indolent course of the disease.